Hyperbaric Oxygen Therapy Versus High Power Laser for Diabetic Neuropathy (HBOT-HPLT-DPN)
Hyperbaric Oxygen Therapy Versus High Power Laser Therapy On Sensorimotor Functions In Patients With Diabetic Peripheral Neuropathy
The purpose of this study is to compare the clinical effects of Hyperbaric Oxygen Therapy (HBOT) versus High-Intensity Laser Therapy (HPLT) on sensorimotor functions and nerve conduction in patients suffering from painful diabetic peripheral neuropathy.
Participants are divided into three equal groups. The first group receives a traditional physiotherapy program focused on ankle and foot exercises. The second group receives hyperbaric oxygen therapy sessions in addition to the traditional program. The third group receives high-power MLS laser therapy alongside the traditional program. Investigators look at whether either advanced intervention shows superiority in improving nerve functionality and reducing neuropathic pain.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Diabetic peripheral neuropathy (DPN) is a major microvascular complication of diabetes leading to progressive nerve damage and neuropathic pain. This randomized controlled trial evaluates and compares the efficacy of two non-pharmacological interventions: Hyperbaric Oxygen Therapy (HBOT) and High-Intensity Laser Therapy (HPLT).
A total of 66 medically controlled patients with painful diabetic neuropathy are randomly assigned into three equal parallel groups (22 patients per group):
- Control Group (A): Receives a traditional physiotherapy program including foot and ankle ROM exercises, strengthening, and functional walking training for 5 sessions per week for 3 weeks.
- Study Group (B): Receives Hyperbaric Oxygen Therapy (100% oxygen at 2.5 ATA for 60 minutes, totaling 90 minutes per session) for 15 sessions over 3 weeks, combined with the traditional physiotherapy program.
- Study Group (C): Receives High-Power Laser Therapy using a Multiwave Locked System (MLS) laser device (1500 Hz frequency) applied every other day for 9 sessions over 3 weeks, combined with the traditional physiotherapy program.
Assessments are conducted before and after the 3-week treatment period using objective Nerve Conduction Studies (NCS) for the sural and common peroneal nerves, and subjective screening via the Arabic Michigan Neuropathy Screening Instrument (MNSI) score.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypte, 11771
- Kobri El Koba Military Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients diagnosed with type 2 diabetes mellitus for more than 5 years.
- Presence of painful diabetic peripheral neuropathy lasting for more than 6 months.
- Presence of sensory abnormalities, burning pain, and impaired nerve conduction velocity in the lower extremities.
- Medically controlled glycemic status.
- Sufficient cognitive abilities with a Mini-Mental State Examination (MMSE) score greater than 24.
- Fit for hyperbaric pressure therapy with a cardiac ejection fraction (CEF) equal to or greater than 50% and blood pressure equal to or less than 150/90 mmHg.
Exclusion Criteria:
- Peripheral neuropathy resulting from causes other than diabetes (e.g., vitamin B12 deficiency, alcohol abuse, or trauma).
- Severe vascular insufficiency in the lower limbs.
- Uncontrolled medical conditions such as tumors or thyroid dysfunction.
- Pregnancy.
- Presence of metallic implantations or cardiac pacemakers.
- Severe visual, auditory, or cognitive impairment (MMSE score less than 24).
- Chronic obstructive pulmonary disease (COPD) or other contraindications to hyperbaric oxygen therapy.
- History of other neurological diseases (e.g., stroke or multiple sclerosis).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Conventional Physiotherapy
Foot and ankle range of motion (ROM) exercises, strengthening exercises, functional exercises, and walking training (5 sessions per week for 3 weeks). |
Foot and ankle range of motion (ROM) exercises, strengthening exercises, functional exercises, and walking training (5 sessions per week for 3 weeks) |
|
Experimenteel: Hyperbaric Oxygen Therapy (HBOT)
Conventional physiotherapy program plus HBOT sessions (100% oxygen at 2.5 ATA for 60 minutes, with 15 minutes gradual compression and 15 minutes decompression, totaling 90 minutes per session). 15 sessions over 3 weeks. |
100% oxygen inhalation at 2.5 ATA pressure for 60 minutes inside a hyperbaric chamber.
Andere namen:
|
|
Experimenteel: High-Power Laser Therapy (HPLT)
Conventional physiotherapy program plus HPLT (MLS laser, M6). Applied every other day for 9 sessions over 3 weeks. Includes a remote foot scan followed by contact application on 7 specific lower extremity areas. |
MLS laser (M6 device) at 1500 Hz frequency, applied every other day for 9 sessions over 3 weeks. Includes a remote foot scan followed by contact application on 7 specific lower extremity areas.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Michigan Neuropathy Screening Instrument (MNSI) score
Tijdsspanne: Baseline and 3 weeks post-treatment
|
The Michigan Neuropathy Screening Instrument (MNSI) questionnaire was used to assess symptoms of diabetic peripheral neuropathy. Abnormal responses were summed to obtain the total score. The questionnaire score ranges from 0 to 13, with higher scores indicating greater neuropathic symptom burden. |
Baseline and 3 weeks post-treatment
|
|
Change in right sural nerve distal sensory latency
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Right sural nerve distal sensory latency was assessed using nerve conduction studies and measured in milliseconds (ms). |
Baseline and after 3 weeks of treatment
|
|
Change in left sural nerve distal sensory latency
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Left sural nerve distal sensory latency was assessed using nerve conduction studies and measured in milliseconds (ms). |
Baseline and after 3 weeks of treatment
|
|
Change in right sural nerve sensory amplitude
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Right sural nerve sensory amplitude was assessed using nerve conduction studies and measured in microvolts (µV). |
Baseline and after 3 weeks of treatment
|
|
Change in left sural nerve sensory amplitude
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Left sural nerve sensory amplitude was assessed using nerve conduction studies and measured in microvolts (µV). |
Baseline and after 3 weeks of treatment
|
|
Change in right sural nerve conduction velocity
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Right sural nerve conduction velocity was assessed using nerve conduction studies and measured in meters per second (m/s). |
Baseline and after 3 weeks of treatment
|
|
Change in left sural nerve conduction velocity
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Left sural nerve conduction velocity was assessed using nerve conduction studies and measured in meters per second (m/s). |
Baseline and after 3 weeks of treatment
|
|
Change in right peroneal nerve distal motor latency
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Right peroneal nerve distal motor latency was assessed using nerve conduction studies and measured in milliseconds (ms). |
Baseline and after 3 weeks of treatment
|
|
Change in left peroneal nerve distal motor latency
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Left peroneal nerve distal motor latency was assessed using nerve conduction studies and measured in milliseconds (ms). |
Baseline and after 3 weeks of treatment
|
|
Change in right peroneal nerve motor amplitude
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Right peroneal nerve motor amplitude was assessed using nerve conduction studies and measured in millivolts (mV). |
Baseline and after 3 weeks of treatment
|
|
Change in left peroneal nerve motor amplitude
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Left peroneal nerve motor amplitude was assessed using nerve conduction studies and measured in millivolts (mV). |
Baseline and after 3 weeks of treatment
|
|
Change in right peroneal nerve motor conduction velocity
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Right peroneal nerve motor conduction velocity was assessed using nerve conduction studies and measured in meters per second (m/s). |
Baseline and after 3 weeks of treatment
|
|
Change in left peroneal nerve motor conduction velocit
Tijdsspanne: Baseline and after 3 weeks of treatment
|
Left peroneal nerve motor conduction velocity was assessed using nerve conduction studies and measured in meters per second (m/s). |
Baseline and after 3 weeks of treatment
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- P.T.REC/012/005181
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data will not be shared outside the research team to maintain patient privacy and data confidentiality in accordance with institutional guidelines.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .